Richard Law

“And I also want to extend out welcome to Terry and look forward to working with him. So a couple of questions for me. I see that you guys have a lot of postings on the territorial manager positions.”

“So, based on that accelerated approval timeline, I believe you mentioned in the past that only a small clinical team will be unblinded to review the interim phase three results and management will still be blinded.”

“The first is, we saw sales from other products from many other companies impacted by the severity of weather in Q1. Was there any seasonal effects that could have impeded personified sales or moment form in Q1?”

“Do you get a sense that you need to compete with AZ on preferred or exclusive access of payers based on some of the discussions that you're having? And also, what is your confidence level on getting access to that 3L setting compared to fourth and the fifth L setting?”

“Yeah, very helpful to see Cass's development all laid out in his life for all the different lines of therapy. A couple of questions from me.”